A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis

Part of paid clinical trials in New York, New York.

Sponsor
Eli Lilly and Company
Study ID
NCT02387801
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To detect onset of activity of ixekizumab in participants with moderate-to-severe plaque psoriasis and to document the same using sequential photographic images.

Key Dates

Start date
Apr 30, 2015
Status verified
Sep 2019
Primary completion
Sep 30, 2015
Completion
Aug 31, 2016

Study Design

Enrollment
12 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Ixekizumab Dosing Q2W
    160 milligrams (mg) ixekizumab given as two subcutaneous (SC) injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once (Q2W) every 2 weeks through week 12. After week 12 participants will receive 80 mg ixekizumab every 4 weeks through week 44.
  • Experimental: Ixekizumab Dosing Q4W
    160 mg ixekizumab given as two SC injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once (Q4W) every 4 weeks through week 44.

Primary Outcome Measure

Time to at Least a 1 Point Improvement on the Patient's Global Assessment of Disease Severity (PatGA) Score [ Time Frame: Baseline through Week 12 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Mount Sinai School of Medicine Dermatology Clinical TrialsNew YorkNew York10029-

Find similar trials in New York, NY

By condition
Psoriasis
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Mount Sinai School of Medicine Dermatology Clinical Trials· New York, NY

Related Studies